ProMIS Neurosciences, Inc.
PMNHealthcare|Biotechnology|CA
$4.16
+0.51 (+13.97%)
DCF Value
$1.51
Tangible Book / Share
$5.40
Cash / Share
$5.85
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06750432 PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Alzheimer Disease, Early Onset | P1 | Active | 144 | RCT, Double-blind | PMN310, Placebo |
| NCT06105528 A Phase 1a Study of PMN310 In Healthy Volunteers | Healthy Participants | P1 | Completed | 40 | RCT, Double-blind | PMN310, Placebo |